Literature DB >> 14977832

Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples.

Lee-Yung Shih1, Chein-Fuang Huang, Jin-Hou Wu, Po-Nan Wang, Tung-Liang Lin, Po Dunn, Meng-Chu Chou, Ming-Chung Kuo, Chung-Chih Tang.   

Abstract

PURPOSE: We analyzed Asp(835) mutations of FLT3 on paired marrow samples at diagnosis and relapse from 120 adult patients with de novo acute myeloid leukemia (AML) to determine the role of FLT3 Asp(835) mutation in the relapse of AML. EXPERIMENTAL
DESIGN: Asp(835) mutation was analyzed by DNA PCR amplification of exon 20 of FLT3 gene followed by EcoRV digestion. All of the mutations were confirmed by sequence analysis. Mutant to wild-type allelic ratio was determined by Genescan analysis. The Expand Long Template PCR System was used to determine the allelic location of internal tandem duplication of FLT3 (FLT3/ITD) and Asp(835) mutations.
RESULTS: Thirteen patients had Asp(835) mutations at diagnosis, of them 8 lost the mutations at relapse, and the remaining 5 patients carrying Asp(835) mutations at diagnosis relapsed with the identical mutation types. Another 6 patients acquired Asp(835) mutations at relapse. Five samples harbored both FLT3/ITD and Asp(835) mutations that were found on different alleles by cloning analysis in the 3 patients studied. There were no differences in WBC count, French-American-British subtype, percentage of marrow blasts, or circulating blasts between patients with and without Asp(835) mutations, whereas the difference in the prevalence of Asp(835) mutations among cytogenetic/molecular subgroups was statistically significant (P = 0.025).
CONCLUSIONS: The present study showed that patients with AML had heterogeneous patterns of FLT3 Asp(835) mutations, either acquisition or loss of the mutations at relapse. Asp(835) mutant clone may develop as a secondary event in a subset of patients with AML.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14977832     DOI: 10.1158/1078-0432.ccr-0835-03

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

Review 1.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

Review 2.  Clinical significance of FLT3 in leukemia.

Authors:  Hitoshi Kiyoi; Masamitsu Yanada; Kazutaka Ozekia
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

3.  The origin and evolution of mutations in acute myeloid leukemia.

Authors:  John S Welch; Timothy J Ley; Daniel C Link; Christopher A Miller; David E Larson; Daniel C Koboldt; Lukas D Wartman; Tamara L Lamprecht; Fulu Liu; Jun Xia; Cyriac Kandoth; Robert S Fulton; Michael D McLellan; David J Dooling; John W Wallis; Ken Chen; Christopher C Harris; Heather K Schmidt; Joelle M Kalicki-Veizer; Charles Lu; Qunyuan Zhang; Ling Lin; Michelle D O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Lucinda A Fulton; Vincent J Magrini; Sean D McGrath; Ryan T Demeter; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd N Wylie; Jason R Walker; Mark A Watson; Sharon E Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Jacqueline E Payton; Jack D Baty; Shashikant Kulkarni; Jeffery M Klco; Michael H Tomasson; Peter Westervelt; Matthew J Walter; Timothy A Graubert; John F DiPersio; Li Ding; Elaine R Mardis; Richard K Wilson
Journal:  Cell       Date:  2012-07-20       Impact factor: 41.582

4.  A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia.

Authors:  Hsiao-Wen Kao; Masashi Sanada; Der-Cherng Liang; Chang-Liang Lai; En-Hui Lee; Ming-Chung Kuo; Tung-Liang Lin; Yu-Shu Shih; Jin-Hou Wu; Chein-Fuang Huang; Seishi Ogawa; Lee-Yung Shih
Journal:  Neoplasia       Date:  2011-11       Impact factor: 5.715

5.  Analyses of minimal residual disease based on Flt3 mutations in allogeneic peripheral blood stem cell transplantation.

Authors:  Sebastian Scholl; Ivan F Loncarevic; Claudia Krause; Joachim H Clement; Klaus Höffken; Herbert G Sayer
Journal:  J Cancer Res Clin Oncol       Date:  2005-01-11       Impact factor: 4.553

6.  Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

Authors:  Todd D Prickett; Neena S Agrawal; Xiaomu Wei; Kristin E Yates; Jimmy C Lin; John R Wunderlich; Julia C Cronin; Pedro Cruz; Steven A Rosenberg; Yardena Samuels
Journal:  Nat Genet       Date:  2009-08-30       Impact factor: 38.330

Review 7.  Clinical implications of molecular genetic aberrations in acute myeloid leukemia.

Authors:  Sebastian Scholl; Hans-Joerg Fricke; Herbert G Sayer; Klaus Höffken
Journal:  J Cancer Res Clin Oncol       Date:  2009-01-06       Impact factor: 4.553

8.  Distinct association between aberrant methylation of Wnt inhibitors and genetic alterations in acute myeloid leukaemia.

Authors:  H-A Hou; Y-Y Kuo; C-Y Liu; M C Lee; J-L Tang; C-Y Chen; W-C Chou; C-F Huang; F-Y Lee; M-C Liu; M Yao; H-F Tien
Journal:  Br J Cancer       Date:  2011-11-17       Impact factor: 7.640

9.  Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.

Authors:  Hanna Janke; Friederike Pastore; Daniela Schumacher; Tobias Herold; Karl-Peter Hopfner; Stephanie Schneider; Wolfgang E Berdel; Thomas Büchner; Bernhard J Woermann; Marion Subklewe; Stefan K Bohlander; Wolfgang Hiddemann; Karsten Spiekermann; Harald Polzer
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

10.  The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).

Authors:  Sarit Assouline; Eftihia Cocolakis; Katherine L B Borden
Journal:  Cancers (Basel)       Date:  2012-11-02       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.